Ionis Pharmaceuticals Reports Q4 Earnings Miss Amid Investor Conference Participation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy IONS?
Source: seekingalpha
Ionis Pharmaceuticals Inc. shares fell 5.11% as the stock crossed below its 5-day SMA, reflecting investor concerns following its recent earnings report.
The company reported a Q4 GAAP EPS of -$1.41, missing expectations by $0.09, alongside a revenue decline of 10.6% year-over-year, despite exceeding market expectations. Ionis also provided a cautious outlook for 2026, projecting revenue between $800 million and $825 million, driven by the anticipated launch of Olezarsen, which may help improve future performance.
The combination of disappointing earnings and a cautious outlook has raised concerns among investors, leading to the stock's decline. However, the upcoming participation in multiple investor conferences may provide opportunities for the company to address these concerns and showcase its innovative pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.150
Low
65.00
Averages
92.67
High
110.00
Current: 81.150
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ionis Pharmaceuticals Unveils New Data for DAWNZERA at AAAAI 2026
- Clinical Data Presentation: Ionis Pharmaceuticals will present new data for DAWNZERA (donidalorsen) at the 2026 AAAAI Annual Meeting, emphasizing its clinical value for hereditary angioedema (HAE) patients, potentially leading to significant improvements in attack frequency and quality of life.
- Research Highlights: The presentation includes analyses from the OASIS-HAE and OASISplus studies, indicating DAWNZERA's appeal in long-term prophylactic treatment, particularly for patients switching from other therapies, showcasing its competitive market potential.
- Extensive Poster Displays: Ionis will conduct eight poster presentations at the conference, covering various aspects from patient-reported disease control to unmet treatment needs, further solidifying its leadership position in HAE treatment.
- Broad Market Prospects: With HAE affecting over 20,000 individuals, DAWNZERA, as the first RNA-targeted medicine, is expected to become the prophylactic treatment of choice for HAE patients, addressing their urgent need for reduced attack frequency and severity.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Olezarsen
- FDA Priority Review: Ionis Pharmaceuticals announced that its drug olezarsen for severe hypertriglyceridemia has received FDA Priority Review, with a PDUFA target date of June 30, 2026, which will expedite its market entry to meet urgent patient needs for new treatment options.
- Clinical Trial Results: In the Phase 3 CORE and CORE2 studies, olezarsen demonstrated a statistically significant reduction in triglyceride levels of up to 72% and an 85% reduction in acute pancreatitis events, indicating its substantial potential to improve patient health outcomes.
- Market Demand: Approximately 3 million people in the U.S. suffer from severe hypertriglyceridemia, with over 1 million classified as high-risk; the limited efficacy of current treatments highlights the critical need for olezarsen to provide new hope and reduce the risk of acute pancreatitis.
- Drug Mechanism: Olezarsen works by lowering the production of apoC-III in the liver, which regulates triglyceride metabolism, and is already approved in the U.S. and EU for patients with familial chylomicronemia syndrome, showcasing its broad application prospects in treating hypertriglyceridemia.
See More
Ionis Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Ionis Pharmaceuticals reported $944 million in revenue for 2025, a 34% year-over-year increase, with commercial product sales contributing $436 million and R&D collaborations generating $508 million, showcasing the company's strong market performance and diversified revenue streams.
- Successful Product Launches: The independent launches of TRYNGOLZA and DAWNZERA mark a significant milestone for Ionis in 2025, with TRYNGOLZA exceeding market expectations and DAWNZERA projected to exceed $500 million in sales potential, further solidifying the company's market position.
- Positive R&D Progress: Olezarsen achieved positive Phase III results in severe hypertriglyceridemia and received FDA breakthrough therapy designation, with plans to be launch-ready by June 2026, demonstrating the company's robust capabilities in drug development.
- Management Change: Ionis announced Holly Kordasiewicz as the new Chief Development Officer, reflecting strategic adjustments in the executive team to support future product development and market expansion.
See More
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results
- Financial Performance Beat: Ionis Pharmaceuticals reported an adjusted loss of $1.15 for Q4, better than Wall Street's estimate of $1.32, although the stock is under pressure, indicating market concerns about future performance.
- Significant Sales Growth: The company achieved $203 million in sales for Q4, surpassing the consensus of $156.09 million, primarily driven by strong sales of Tryngolza (olezarsen), which contributed to a 64% year-over-year increase.
- Product Sales Highlights: Tryngolza generated net product sales of $50 million in Q4, a 56% increase over the prior quarter, while Dawnzera (donidalorsen) recorded $7 million in its first full quarter on the market, indicating strong market acceptance of new products.
- Cautious Future Outlook: Ionis expects fiscal 2026 sales between $800 million and $825 million, below the consensus of $909.84 million, and anticipates an adjusted operating loss of $500 million to $550 million, reflecting a cautious approach to future growth.
See More
Ionis Pharmaceuticals Q4 2023 Earnings Report Analysis
- Earnings Performance: Ionis Pharmaceuticals reported a Q4 GAAP EPS of -$1.41, missing expectations by $0.09, indicating challenges in profitability that may affect investor confidence.
- Revenue Situation: The company generated $203 million in revenue for Q4, a 10.6% year-over-year decline, yet it exceeded market expectations by $46.87 million, demonstrating some resilience in revenue despite challenges.
- 2026 Outlook: Ionis projects revenue between $800 million and $825 million for 2026, reflecting cautious optimism about future growth, particularly with the anticipated launch of Olezarsen potentially driving revenue increases.
- Operating Loss Expectations: The company expects a non-GAAP operating loss of $500 million to $550 million in 2026, indicating ongoing investments in R&D and marketing, which may exert pressure on short-term financial performance.
See More
Ionis Pharmaceuticals to Announce Q4 Earnings on February 25
- Earnings Announcement: Ionis Pharmaceuticals is set to release its Q4 2023 earnings report on February 25 before market open, with consensus EPS estimated at -$1.22 and revenue at $156.13 million, reflecting a significant 31.2% year-over-year decline, indicating challenges the company is facing in the current market environment.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates experienced five upward revisions and three downward changes, highlighting analysts' differing views on Ionis's future performance, which could impact investor confidence.
- Product Launch Outlook: Ionis anticipates the 2026 launch of Olezarsen for SHTG treatment, which is expected to spur revenue growth, demonstrating the company's ongoing commitment to research and development and its strategic market expansion efforts.
- Regulatory Progress: Ionis, in collaboration with Otsuka, has received EU approval for a therapy for hereditary angioedema and has been granted FDA breakthrough therapy status, showcasing the company's positive advancements in innovative drug development, potentially laying a foundation for future market performance.
See More
Ionis Pharmaceuticals Unveils New Data for DAWNZERA at AAAAI 2026
- Clinical Data Presentation: Ionis Pharmaceuticals will present new data for DAWNZERA (donidalorsen) at the 2026 AAAAI Annual Meeting, emphasizing its clinical value for hereditary angioedema (HAE) patients, potentially leading to significant improvements in attack frequency and quality of life.
- Research Highlights: The presentation includes analyses from the OASIS-HAE and OASISplus studies, indicating DAWNZERA's appeal in long-term prophylactic treatment, particularly for patients switching from other therapies, showcasing its competitive market potential.
- Extensive Poster Displays: Ionis will conduct eight poster presentations at the conference, covering various aspects from patient-reported disease control to unmet treatment needs, further solidifying its leadership position in HAE treatment.
- Broad Market Prospects: With HAE affecting over 20,000 individuals, DAWNZERA, as the first RNA-targeted medicine, is expected to become the prophylactic treatment of choice for HAE patients, addressing their urgent need for reduced attack frequency and severity.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Olezarsen
- FDA Priority Review: Ionis Pharmaceuticals announced that its drug olezarsen for severe hypertriglyceridemia has received FDA Priority Review, with a PDUFA target date of June 30, 2026, which will expedite its market entry to meet urgent patient needs for new treatment options.
- Clinical Trial Results: In the Phase 3 CORE and CORE2 studies, olezarsen demonstrated a statistically significant reduction in triglyceride levels of up to 72% and an 85% reduction in acute pancreatitis events, indicating its substantial potential to improve patient health outcomes.
- Market Demand: Approximately 3 million people in the U.S. suffer from severe hypertriglyceridemia, with over 1 million classified as high-risk; the limited efficacy of current treatments highlights the critical need for olezarsen to provide new hope and reduce the risk of acute pancreatitis.
- Drug Mechanism: Olezarsen works by lowering the production of apoC-III in the liver, which regulates triglyceride metabolism, and is already approved in the U.S. and EU for patients with familial chylomicronemia syndrome, showcasing its broad application prospects in treating hypertriglyceridemia.
See More
Ionis Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Ionis Pharmaceuticals reported $944 million in revenue for 2025, a 34% year-over-year increase, with commercial product sales contributing $436 million and R&D collaborations generating $508 million, showcasing the company's strong market performance and diversified revenue streams.
- Successful Product Launches: The independent launches of TRYNGOLZA and DAWNZERA mark a significant milestone for Ionis in 2025, with TRYNGOLZA exceeding market expectations and DAWNZERA projected to exceed $500 million in sales potential, further solidifying the company's market position.
- Positive R&D Progress: Olezarsen achieved positive Phase III results in severe hypertriglyceridemia and received FDA breakthrough therapy designation, with plans to be launch-ready by June 2026, demonstrating the company's robust capabilities in drug development.
- Management Change: Ionis announced Holly Kordasiewicz as the new Chief Development Officer, reflecting strategic adjustments in the executive team to support future product development and market expansion.
See More
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results
- Financial Performance Beat: Ionis Pharmaceuticals reported an adjusted loss of $1.15 for Q4, better than Wall Street's estimate of $1.32, although the stock is under pressure, indicating market concerns about future performance.
- Significant Sales Growth: The company achieved $203 million in sales for Q4, surpassing the consensus of $156.09 million, primarily driven by strong sales of Tryngolza (olezarsen), which contributed to a 64% year-over-year increase.
- Product Sales Highlights: Tryngolza generated net product sales of $50 million in Q4, a 56% increase over the prior quarter, while Dawnzera (donidalorsen) recorded $7 million in its first full quarter on the market, indicating strong market acceptance of new products.
- Cautious Future Outlook: Ionis expects fiscal 2026 sales between $800 million and $825 million, below the consensus of $909.84 million, and anticipates an adjusted operating loss of $500 million to $550 million, reflecting a cautious approach to future growth.
See More
Ionis Pharmaceuticals Q4 2023 Earnings Report Analysis
- Earnings Performance: Ionis Pharmaceuticals reported a Q4 GAAP EPS of -$1.41, missing expectations by $0.09, indicating challenges in profitability that may affect investor confidence.
- Revenue Situation: The company generated $203 million in revenue for Q4, a 10.6% year-over-year decline, yet it exceeded market expectations by $46.87 million, demonstrating some resilience in revenue despite challenges.
- 2026 Outlook: Ionis projects revenue between $800 million and $825 million for 2026, reflecting cautious optimism about future growth, particularly with the anticipated launch of Olezarsen potentially driving revenue increases.
- Operating Loss Expectations: The company expects a non-GAAP operating loss of $500 million to $550 million in 2026, indicating ongoing investments in R&D and marketing, which may exert pressure on short-term financial performance.
See More
Ionis Pharmaceuticals to Announce Q4 Earnings on February 25
- Earnings Announcement: Ionis Pharmaceuticals is set to release its Q4 2023 earnings report on February 25 before market open, with consensus EPS estimated at -$1.22 and revenue at $156.13 million, reflecting a significant 31.2% year-over-year decline, indicating challenges the company is facing in the current market environment.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates experienced five upward revisions and three downward changes, highlighting analysts' differing views on Ionis's future performance, which could impact investor confidence.
- Product Launch Outlook: Ionis anticipates the 2026 launch of Olezarsen for SHTG treatment, which is expected to spur revenue growth, demonstrating the company's ongoing commitment to research and development and its strategic market expansion efforts.
- Regulatory Progress: Ionis, in collaboration with Otsuka, has received EU approval for a therapy for hereditary angioedema and has been granted FDA breakthrough therapy status, showcasing the company's positive advancements in innovative drug development, potentially laying a foundation for future market performance.
See More
